Abevmy (bevacizumab)

pCPA File Number: 21437

Negotiation Status:

Concluded with an LOI

Indication(s):

Metastatic colorectal cancer (mCRC), locally advanced, metastatic or recurrent non-small cell lung Cancer (NSCLC), platinum-resistant recurrent epithelial ovarian, fallopian tube and primary peritoneal cancer, and glioblastoma

Sponsor/Manufacturer:

BGP Pharma ULC

CDA-AMC Project Number:

Not Applicable

pCPA Engagement Letter Issued:

2021-06-11

Negotiation Process Concluded:

2021-10-25